Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Nektar Therapeutics buy BiotechBee

Nektar Therapeutics
Start price
€1.59
15.04.24 / 70%
Target price
€2.40
28.02.26
Performance (%)
-14.76%
Price
€1.36
22:26
Summary
This prediction is currently active. The prediction for Nektar Therapeutics disappoints with a performance of -14.76%. This prediction currently runs until 28.02.26. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 70% into this prediction

Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.

Performance without dividends (%)
Name 1w
Nektar Therapeutics 4.329%
iShares Core DAX® 2.594%
iShares Nasdaq 100 3.553%
iShares Nikkei 225® 0.687%
iShares S&P 500 2.209%

According to BiotechBee what are the pros and cons of Nektar Therapeutics for the foreseeable future?

Pros
Could be very worthwhile Investment >20% year
Cons

Comments by BiotechBee for this prediction

In the thread Nektar Therapeutics diskutieren
Prediction Buy
Perf. (%) -14.76%
Target price 2.400
Change
Ends at 28.02.26

Buy mit Kursziel 2,4

BiotechBee 
0
Report Share
15.04.24